Tumor necrosis factor alpha inhibits signaling from the insulin receptor

G S Hotamisligil, D L Murray, L N Choy, B M Spiegelman, G S Hotamisligil, D L Murray, L N Choy, B M Spiegelman

Abstract

Insulin resistance is a common problem associated with infections and cancer and, most importantly, is the central component of non-insulin-dependent diabetes mellitus. We have recently shown that tumor necrosis factor (TNF) alpha is a key mediator of insulin resistance in animal models of non-insulin-dependent diabetes mellitus. Here, we investigate how TNF-alpha interferes with insulin action. Chronic exposure of adipocytes to low concentrations of TNF-alpha strongly inhibits insulin-stimulated glucose uptake. Concurrently, TNF-alpha treatment causes a moderate decrease in the insulin-stimulated autophosphorylation of the insulin receptor (IR) and a dramatic decrease in the phosphorylation of IR substrate 1, the major substrate of the IR in vivo. The IR isolated from TNF-alpha-treated cells is also defective in the ability to autophosphorylate and phosphorylate IR substrate 1 in vitro. These results show that TNF-alpha directly interferes with the signaling of insulin through its receptor and consequently blocks biological actions of insulin.

References

    1. Biochem Biophys Res Commun. 1992 Mar 16;183(2):417-22
    1. J Biol Chem. 1991 Nov 15;266(32):21839-45
    1. J Biol Chem. 1992 Jul 5;267(19):13719-27
    1. J Am Coll Nutr. 1992 Aug;11(4):445-56
    1. J Clin Invest. 1992 Nov;90(5):1839-49
    1. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10350-4
    1. Endocrinology. 1992 Jan;130(1):43-52
    1. J Biol Chem. 1992 Dec 25;267(36):25916-21
    1. Science. 1993 Jan 1;259(5091):87-91
    1. Br J Surg. 1992 Dec;79(12):1361-3
    1. World J Surg. 1992 Jan-Feb;16(1):30-6
    1. Cell. 1993 May 21;73(4):625-7
    1. Science. 1993 Sep 17;261(5128):1591-4
    1. J Biol Chem. 1993 Dec 15;268(35):26055-8
    1. Endocrinology. 1994 Jan;134(1):264-70
    1. Nature. 1970 Aug 15;227(5259):680-5
    1. Eur J Clin Invest. 1975 Jul 29;5(4):331-7
    1. Surg Clin North Am. 1976 Oct;56(5):1169-84
    1. Science. 1982 Jan 8;215(4529):185-7
    1. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7797-801
    1. Science. 1985 Aug 30;229(4716):867-9
    1. Nature. 1985 Nov 14-20;318(6042):183-6
    1. Diabetes. 1987 Jan;36(1):123-6
    1. Lab Invest. 1987 Mar;56(3):234-48
    1. Br J Surg. 1987 Nov;74(11):1031-5
    1. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6802-5
    1. Arch Surg. 1988 Nov;123(11):1383-8
    1. Annu Rev Immunol. 1989;7:625-55
    1. Nature. 1989 Jul 6;340(6228):72-4
    1. Science. 1989 Jul 7;245(4913):60-3
    1. J Clin Endocrinol Metab. 1989 Aug;69(2):317-23
    1. J Clin Invest. 1989 Aug;84(2):404-11
    1. J Biol Chem. 1989 Nov 25;264(33):19994-9
    1. Biochem Biophys Res Commun. 1989 Nov 30;165(1):429-36
    1. J Biol Chem. 1990 May 15;265(14):7994-8000
    1. Diabetes. 1990 Feb;39(2):250-9
    1. Diabetologia. 1990 Oct;33(10):625-7
    1. Diabetes. 1991 Apr;40(4):413-22
    1. Biotherapy. 1991;3(2):143-58
    1. Nature. 1991 Jul 4;352(6330):73-7
    1. Am J Physiol. 1991 Oct;261(4 Pt 1):E457-65
    1. Diabetes Res Clin Pract. 1992 Mar;15(3):213-8

Source: PubMed

3
Subskrybuj